AstraZeneca says Brilinta anti-clotting drug reduces chance of dying better than PlavixAugust 30th, 2009 New AstraZeneca drug reduces heart patients' risksBARCELONA, Spain — A new drug to prevent blood clots in heart patients reduced their chances of dying by more than 20 percent compared with the standard treatment, new research says. Researchers followed 18,624 patients worldwide from 2006 to 2008.
Big pharma: Prescription sales and growth trends of the world's top 20 drugmakersAugust 7th, 2009 Ranking Rx: Top 20 drugmakers by annual salesRankings of the world's Top 20 drugmakers, based on global prescription drug sales for the year ending in March 2009, when total pharmaceutical industry revenue grew about 5 percent to more than $720 billion. Figures do not include revenue of company units selling consumer and animal health products, medical devices or diagnostic products.
Strong sales, cost cuts boost drugmaker Bristol-Myers Squibb's 2Q profit 29 percentJuly 23rd, 2009 Strong sales boost Bristol-Myers 2Q profitTRENTON, N.J. — Bristol-Myers Squibb Co.
US stock futures point to higher open after mixed report on labor market, upbeat earningsJuly 23rd, 2009 Stock futures hold on to gains after labor dataNEW YORK — Stock futures are holding on to early gains despite a report showing a bigger-than-expected rise in new jobless claims. The Labor Department says the number of new claims for unemployment benefits rose by 30,000 last week to a seasonally adjusted 554,000, up from the previous week and more than economists had been expecting.
Stocks extend rally after jump in home sales; Dow crosses 9,000 for first time since JanuaryJuly 23rd, 2009 Dow tops 9,000 as home sales rise for 3rd monthNEW YORK — Investors celebrated news of another jump in home sales by propelling the Dow Jones industrials to their first close above 9,000 since January. The stock market's best-known indicator shot up almost 190 points Thursday to 9,069.29, its highest level since November, and all the big indexes gained more than 2 percent.
Stocks hold on to recent gains after latest earnings, mixed report on jobs marketJuly 23rd, 2009 Stocks hold steady amid latest earningsNEW YORK — Stocks are holding on to recent gains, buoyed by the latest string of earnings reports. The day's earnings news was generally positive.
US stock futures slightly higher after latest earnings, mixed report on jobs marketJuly 23rd, 2009 Stock futures slightly higher amid latest earningsNEW YORK — U.S. stock futures are pointing to a slightly higher opening Thursday amid a barrage of earnings news.
US stock futures point to higher open after upbeat earnings, mixed report on labor marketJuly 23rd, 2009 Stock futures push higher amid earnings, jobs dataNEW YORK — U.S. stock futures are rising Thursday amid news of dealmaking and a barrage of upbeat earnings reports.
US stock futures point to higher open amid merger-and-acquisition activity, more earningsJuly 23rd, 2009 Stock futures push higher amid latest earningsNEW YORK — U.S. stock futures are pushing higher Thursday amid news of dealmaking and a barrage of earnings reports.
Antigenics says it appointed former Sanofi-Aventis US head Timothy Rothwell to its boardJune 15th, 2009 Antigenics names former Sanofi US CEO to boardLEXINGTON, Mass. — Biotechnology company Antigenics Inc.
Bristol Palin's dad asked her to dump Levi Johnston and get a car: MagMay 29th, 2009 NEW YORK - Alaska Governor Sarah Palin's husband Todd asked daughter Bristol to dump Levi Johnston and get a car, a magazine has claimed. While in an interview with GQ magazine, Johnston, the baby daddy of Sarah's first grandson, said there's very little chance he'll reunite with Bristol, 18.
Unwed mother Bristol Palin, governor's daughter, joining teen pregnancy prevention campaignMay 5th, 2009 Bristol Palin promotes teen pregnancy preventionANCHORAGE, Alaska — Unwed mother Bristol Palin is going to take part in a national campaign to help raise awareness for teen pregnancy prevention. The 18-year-old daughter of Alaska Gov.
Correction: Drugmaker dollars storyMay 1st, 2009 Correction: Drugmaker dollars storyWASHINGTON — In several versions of an April 28 story about a report on the influence of drugmaker money in medicine, The Associated Press reported erroneously that the head of Stanford University's psychiatry department had stepped down under criticism by a U.S. senator over payments made to him by drugmakers.
Bank of America, Office Depot, GM, Bristol-Myers Squibb are big market movers TuesdayApril 28th, 2009 Bank of America, Office Depot, GM big moversNEW YORK — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and Nasdaq Stock Market:
NYSE
Bank of America Corp., down 77 cents at $8.15
Sources said the bank will need to raise more cash if it can't convince the government its "stress test" results are in error. Office Depot Inc., up 29 cents at $2.82
The office products chain posted a loss, but excluding charges relating to store closings, results were better than analysts expected.
Bristol Palin's ex fiance says he's not mature enough to get marriedMarch 16th, 2009 NEW YORK - The former fiance of Bristol Palin has said that he and the Alaska Governor Sarah Palin's daughter could reunite in the future but would remain apart for now. In an interview to air on "Good Morning America," Levi Johnston said that he needs time to mature before getting married.
Loading ...
July 25th, 2009 at 6:51 pm
Medarex shareholders have taken extrordinary risks over the years with this company. Now that Medarex is about to capitalize on its pipeline, BMS is offering medarex shareholders a fraction of what this company is truly worth
The fact that Medarex management negotiated and accepted an offer of $16.00 dollars per-share is an outrage.
Considering the long-term benefits to BMS and the fact that Ulti-mab antibody platform is the Gold Standard in human antibody technology, it is clear to me that Medarex Management should have attempted to obtain a better price for their shareholders.
Depending on many factor BMS stands to make between 6 and 10 billion dollars and possibly more over the next decade, as antibodies generated by medarex technology achieve market status.
The fact that Mr. Pien, current Medarex CEO isgoing to be paid a muti-million dollar bonus is very disconcerting outrage as well.Medarex shareholders can do better than this